Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 3, 2010, Pages 82-88

  Sanak, Marek ^a   Plutecka, Hanna ^a   Szczeklik, Wojciech ^a   Piwowarska, Wiesława ^a   Rostoff, Paweł ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Coronary heart disease; Cyclooxygenase 2; Inflammatory response; Promoter polymorphism

Indexed keywords

CD163 ANTIGEN; CYCLOOXYGENASE 2; PROSTAGLANDIN E2;

ADULT; AGED; ALLELE; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROMOTER REGION; PROSTAGLANDIN METABOLISM; URINARY EXCRETION;

EID: 77951002867     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.893     Document Type: Article

References (21)

1. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999; 14: 115-126.
2. Szczeklik A, Gryglewski RJ, Niżankowski R, et al. Circulatory and antiplatelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun. 1978; 10: 545-556. (Pubitemid 8402974)
3. Szczeklik A, Gryglewski RJ. Actions of prostacyclin in man. In: Vane JR, Bergstorm S, eds. Prostacyclin. New York, NY: Raven Press; 1979: 393-409.
4. Wang M, Zukas AM, Hui Y, et al. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A. 2006; 103: 14507-14512. (Pubitemid 44484780)
5. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999; 19: 646-655.
6. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002; 22: 1631-1636.
7. Cui JG, Salehi-Rad S, Rogaeva E, et al. Characterization of a cyclooxygenase-2-765G∼>C promoter polymorphism in human neural cells. Neuro Report. 2005; 16: 575-579. (Pubitemid 40586086)
8. Cipollone F, Toniato E, Martinotti S, et al. Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA. 2004; 291: 2221-2228.
9. Colaizzo D, Fofi L, Tiscia G, et al. The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis. 2006; 17: 93-96.
10. Hegener HH, Diehl KA, Kurth T, et al. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost. 2006; 4: 1718-1722. (Pubitemid 44144798)
11. Kohsaka S, Volcik KA, Folsom AR, et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008; 196: 926-930.
12. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol. 2004; 114: 248-253. (Pubitemid 39119020)
13. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, et al. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax. 2008; 63: 27-34.
14. Huuskonen KH, Kunnas TA, Tanner MM, et al. COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm. 2008; 2008: Article ID 289453.
15. Lee CR, North KE, Bray MS, et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther. 2008; 83: 52-60.
16. Orbe J, Beloqui O, Rodriguez JA, et al. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta. 2006; 368: 138-143. (Pubitemid 43776030)
17. McAdam BF, Catella-Lawson F, Mardini I A, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)·2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999; 96: 272-277. (Pubitemid 29036089)
18. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science. 2007; 317: 666-670. (Pubitemid 47229966)
19. Aristoteli LP, Moller HJ, Bailey B, et al. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis. 2006; 184: 342-347. (Pubitemid 43049718)
20. Eligini S, Barbieri SS, Arenaz I, et al. Paracrine up-regulation of monocyte cyclooxygenase-2 by platelets: Role of transforming growth factor-β1. Cardiovasc Res. 2007; 74: 270-278. (Pubitemid 46517508)
21. Skarke C, Reus M, Schmidt R, et al. The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther. 2006; 80: 621-632. (Pubitemid 44908271)